VR Logo

Aileron Therapeutics Inc. (ALRN) download report


Healthcare | Biotechnology & Pharma Research

Aileron Therapeutics Inc. (ALRN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.

IPO Date: 29-Jun-2017

Pres, CEO & Director: Dr. Manuel C. Aivado M.D., Ph.D.

Sr. VP & Chief Medical Officer: Dr. Vojislav Vukovic M.D., Ph.D.

Listing: NASDAQ: ALRN

Country: United States

Headquarters: Boston, MA

Website: https://www.aileronrx.com

Key Facts

Market cap: $22.10 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-27.61 Mln

Cash: $38.08 Mln

Total Debt: $0.13 Mln

Insider's Holding: 9.02%

Liquidity: Low

52 Week range: $0.23 - 1.27

Shares outstanding: 90,823,600

8 Years Aggregate:

  • CFO: $-163.12 Mln
  • EBITDA: $-161.02 Mln
  • Net Profit: $-177.87 Mln

Stock Performance

Time Period Aileron Therapeutics (ALRN) S&P BSE Sensex S&P Small-Cap 600
YTD-53.89-7.86-19.79
1 month-41.27-3.75-9.59
3 months-58.79-10.80-13.28
1 Year-79.061.50-17.92
3 Years-28.1510.755.46
5 Years-53.7811.435.57
10 Years--11.849.48
As on 06-Jul-2022
Year Aileron Therapeutics (ALRN) S&P Small-Cap 600 S&P BSE Sensex
2021-45.8725.2721.99
202081.509.5715.75
2019-31.7920.8614.38
2018-91.92-9.705.87